Injectable pre-exposure prophylaxis (PrEP) is being implemented in certain areas, including Leeds and London, with specific criteria and approval processes in place. The development and rollout of injectable PrEP, including medications such as cabotegravir, are ongoing, with some studies and trials showing its effectiveness. However, the availability and accessibility of injectable PrEP vary, and its rollout appears to be facing delays in some regions.